NCT05255276 - PK Study to Assess Drug-drug Interaction Between Sitravatinib and a P-gp Inducer and an Inhibitor. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 2, 2022

Primary Completion Date

May 12, 2022

Study Completion Date

February 10, 2023

Conditions

Healthy Adults

Interventions

DRUG

Sitravatinib 50 mg

50 mg Sitravatinib on Day 1 (Group 1A)

DRUG

Sitravatinib 100 mg

100 mg Sitravatinib on Day 1 (Group 2A)

DRUG

Itraconazole

Itraconazole QD from Day 9 to Day 18, and Sitravatinib 50 mg at Day 12 (Group 1B)

DRUG

Rifampin

Rifampin QD from Day 9 to Day 22, and Sitravatinib 100 mg at Day 16 (Group 2B)

Trial Locations (1)

Labcorp Drug Development Clinical Research Unit, Dallas